Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”

HHS - 224 - Blood Products Advisory Committee - Authorized by Law


Committee NameBlood Products Advisory CommitteeAgency NameDepartment of Health and Human Services
Fiscal Year2022Committee Number224
Original Establishment Date11/28/1990Committee StatusChartered
Actual Termination Date Committee URL
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*18
Current Charter Date5/13/2022Designated Fed Officer Position Title*Center for Biologics Evaluation and Research, FDA
Date Of Renewal Charter5/13/2024Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*Christina
Exempt From Renewal*NoDesignated Federal Officer Middle NameMarie
Specific Termination AuthorityDesignated Federal Officer Last Name*Vert
Establishment Authority*Authorized by LawDesignated Federal Officer SuffixM.S.
Specific Establishment Authority*21 U.S.C. 394Designated Federal Officer Phone*240-402-8054
Effective Date Of Authority*11/28/1990Designated Federal Officer Fax*301-595-1309
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*
Committee Type*Continuing
Committee Function*Scientific Technical Program Advisory Board


Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The Committee reviews and evaluates data on the safety and effectiveness of blood products intended for use in the diagnosis, prevention or treatment of human diseases.
On November 4, 2021, the committee met by web conference to hear an overview of the research programs of the following CBER laboratories: Plasma Derivatives Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies: Laboratory of Cellular Hematology, Division of Blood Components and Devices, Office of Blood Research and Review (OBRR); and the Laboratory of Emerging Pathogens, Division of Emerging & Transfusion Transmitted Diseases, OBRR, CBER. After each of the open sessions, the meeting was closed to the public to make recommendations to the Agency on specific research programs. The recommendations of the committee were utilized by FDA as part of its independent intramural program review of research priorities. On May 12, 2022, a web conference was held for the combined Laboratory of Emerging Pathogens (LEP) and Laboratory of Molecular Virology (LMV) Site Visit Meeting to evaluate the research programs and to make recommendations to the committee.
How is membership balanced?*The committee consists of experts in clinical and administrative medicine, hematology, immunology, blood banking, surgery, internal medicine, biotechnology, and other related specialties. One member is technically qualified and identified with consumer interests and one non-voting member represents the point of view of industry.
How frequent & relevant are cmte mtgs?*The committee held one advisory committee meeting on Nov 4, 2021 and conducted one intramural laboratory research site visit on May 12, 2022 in FY2022. Three advisory committee meetings and one intramural laboratory research site visit reviews are planned for FY 2023.
Why advice can't be obtained elsewhere?*Members of the committee are drawn from academia, research, clinical practice, and consumer interests. Their advice and input lends credibility to regulatory decisions made and has representatives of knowledge and experience needed from informed sources. The alternate means of obtaining this advice would involve the recruitment of large numbers of scientists on a full-time basis at maximum rates of compensations.
Why close or partially close meetings?This committee held one closed meeting for this fiscal year.
Recommendation RemarksNo reports are required from this committee.


Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*Yes
Outcome Trust In GovernmentYesAction Reallocate ResourcesNo
Outcome Major Policy ChangesYesAction Issued New RegulationsYes
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherYes
Outcome Increased Customer SatisfactionYesAction CommentFDA approves or chooses not to approve an investigational new medical product.
Outcome Implement Laws/Reg RequirementsYesGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentNANumber Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentThe utilization of the Blood Products Advisory Committee enables the Agency to obtain required and frequently scarce professional services from medical and scientific experts not otherwise available to the Agency; and to obtain the services of these experts only on an as needed basis rather than on a full time basis. The service of the Committee resulted in advice for the improvement of the public health, for which it is difficult to assign a financial value.Grants Review CommentNA
Number Of Recommendations*117Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentThe Committee made 117 recommendations from FY2003 through FY2022.Access Agency WebsiteYes
% of Recs Fully Implemented*84.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentThe function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice. This number represents an approximation of the percentage of recommendations that the agency has fully implemented or plans to fully implement.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*10.00%Access PublicationsYes
% of Recs Partially Implemented CommentThe function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.Access OtherNo
Agency Feedback*YesAccess CommentN/A
Agency Feedback Comment*The Agency usually does. Product approval issues are first released to the sponsor. When appropriate, information is made available to the public. Actions related to guidance documents or other general matters issues are available publicly when implemented.Narrative Description*FDA's strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical products; establish an effective tabacco regulation, prevention, and control program; and manage for organizational excellence and accountability. The Blood Product Advisory Committee supports FDA's mission and strategic action plan by reviewing and evaluating data on the safety and effectiveness of blood products intended for use in the diagnosis, prevention or treatment of human diseases. The Committee also considers the quality and relevance of FDA's research program which, provides scientific support for the regulation of these products. The Committee supports FDA's mission by using science-based risk management in all of its activities. The Committee recommendations provide the most health promotion and protection at the least cost for the public. This Committee assists the Agency in ensuring timely, high quality, cost-effective processes for review of new technologies/pre-market submissions, effective communication and working relationships with stakeholders to enhance U.S. and global health outcomes, accurately analyzing risks associated with medical products, facilitating the development and availability of medical countermeasures to limit the effects of a terrorist attack on the civilian and military populations, protecting the safety and security of biologics (vaccines, blood, and blood products) all key components of FDA's strategic plan objectives.
Hide Section - COSTS


Payments to Non-Federal Members*$5,630.00Est Payments to Non-Fed Members Next FY*$23,560.00
Payments to Federal Members*$1,689.00Est. Payments to Fed Members Next FY*$8,246.00
Payments to Federal Staff*$288,614.00Estimated Payments to Federal Staff*$291,327.00
Payments to Consultants*$6,756.00Est. Payments to Consultants Next FY*$7,068.00
Travel Reimb. For Non-Federal Members*$0.00Est Travel Reimb Non-Fed Members nextFY*$0.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$0.00Est Travel Reimb to Consultants Next FY*$0.00
Other Costs$76,515.00Est. Other Costs Next FY*$86,050.00
Total Costs$379,204.00Est. Total Next FY*$416,251.00
Date Cost Last Modified11/8/2022 3:58 PMEst. Fed Staff Support Next FY*1.70
Federal Staff Support (FTE)*1.75Est Cost Remarks
Cost RemarksThe payment to Members (Fed & Non-Fed) and consultants decreased from Charter to ACR, because we have a more accurate count of actual attendees and did not include estimation of projected costs of potential members.
Comparing the FY22 Charter to the ACR, the number of FTE increased from 1.5 to 1.7, and also, payment to Fed Staff increased as we had a new employee start after we submitted the Charter.
The admin overhead decreased because the Charter FY23 included an estimate of costs for AV & transcription, where the ACR FY23 did not. Furthermore, the pricing for the AV (CDRH Studio) decreased because they changed how they bill depending on who supports the meeting.
Hide Section - Interest Areas

Interest Areas

Food and Drugs
Food and Drugs


To View all the members, meetings and advisory reports for this committee please click here


No Documents Found



Data from Previous Years

ActionCommittee System IDCommittee NameFiscal Year
 COM-040370Blood Products Advisory Committee2021
 COM-038648Blood Products Advisory Committee2020
 COM-036519Blood Products Advisory Committee2019
 COM-034727Blood Products Advisory Committee2018
 COM-001614Blood Products Advisory Committee2017
 COM-002604Blood Products Advisory Committee2016
 COM-003858Blood Products Advisory Committee2015
 COM-004545Blood Products Advisory Committee2014
 COM-006090Blood Products Advisory Committee2013
 COM-006546Blood Products Advisory Committee2012
 COM-008407Blood Products Advisory Committee2011
 COM-008764Blood Products Advisory Committee2010
 COM-010019Blood Products Advisory Committee2009
 COM-010706Blood Products Advisory Committee2008
 COM-011985Blood Products Advisory Committee2007
 COM-012687Blood Products Advisory Committee2006
 COM-013802Blood Products Advisory Committee2005
 COM-014500Blood Products Advisory Committee2004
 COM-015942Blood Products Advisory Committee2003
 COM-016554Blood Products Advisory Committee2002
 COM-017916Blood Products Advisory Committee2001
 COM-018726Blood Products Advisory Committee2000
 COM-019774Blood Products Advisory Committee1999
 COM-020377Blood Products Advisory Committee1998
 COM-021428Blood Products Advisory Committee1997